AZD-5423

AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.[1][2][3][4][5]

AZD-5423
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.205.965
Chemical and physical data
FormulaC25H21F4N3O3
Molar mass487.455 g·mol−1
3D model (JSmol)

See also

References
  1. "AZD 5423 - AdisInsight".
  2. C. Drahl, Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA, 2013, http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/
  3. GB2010051905 Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
  4. SE2009050900 A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
  5. SE2009000264 Combination of (a) glucocorticoid receptor modulator and (b) a β2-agonist



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.